111 related articles for article (PubMed ID: 19916508)
1. Morpholine derivatives greatly enhance the selectivity of mammalian target of rapamycin (mTOR) inhibitors.
Zask A; Kaplan J; Verheijen JC; Richard DJ; Curran K; Brooijmans N; Bennett EM; Toral-Barza L; Hollander I; Ayral-Kaloustian S; Yu K
J Med Chem; 2009 Dec; 52(24):7942-5. PubMed ID: 19916508
[TBL] [Abstract][Full Text] [Related]
2. Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 6-aryl substituent.
Verheijen JC; Richard DJ; Curran K; Kaplan J; Lefever M; Nowak P; Malwitz DJ; Brooijmans N; Toral-Barza L; Zhang WG; Lucas J; Hollander I; Ayral-Kaloustian S; Mansour TS; Yu K; Zask A
J Med Chem; 2009 Dec; 52(24):8010-24. PubMed ID: 19894727
[TBL] [Abstract][Full Text] [Related]
3. Identification and optimisation of novel and selective small molecular weight kinase inhibitors of mTOR.
Menear KA; Gomez S; Malagu K; Bailey C; Blackburn K; Cockcroft XL; Ewen S; Fundo A; Le Gall A; Hermann G; Sebastian L; Sunose M; Presnot T; Torode E; Hickson I; Martin NM; Smith GC; Pike KG
Bioorg Med Chem Lett; 2009 Oct; 19(20):5898-901. PubMed ID: 19733066
[TBL] [Abstract][Full Text] [Related]
4. Discovery of 3,6-dihydro-2H-pyran as a morpholine replacement in 6-aryl-1H-pyrazolo[3,4-d]pyrimidines and 2-arylthieno[3,2-d]pyrimidines: ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR).
Kaplan J; Verheijen JC; Brooijmans N; Toral-Barza L; Hollander I; Yu K; Zask A
Bioorg Med Chem Lett; 2010 Jan; 20(2):640-3. PubMed ID: 19963384
[TBL] [Abstract][Full Text] [Related]
5. Discovery of 2-arylthieno[3,2-d]pyrimidines containing 8-oxa-3-azabi-cyclo[3.2.1]octane in the 4-position as potent inhibitors of mTOR with selectivity over PI3K.
Verheijen JC; Yu K; Toral-Barza L; Hollander I; Zask A
Bioorg Med Chem Lett; 2010 Jan; 20(1):375-9. PubMed ID: 19897362
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and SAR of novel 4-morpholinopyrrolopyrimidine derivatives as potent phosphatidylinositol 3-kinase inhibitors.
Chen Z; Venkatesan AM; Dehnhardt CM; Ayral-Kaloustian S; Brooijmans N; Mallon R; Feldberg L; Hollander I; Lucas J; Yu K; Kong F; Mansour TS
J Med Chem; 2010 Apr; 53(8):3169-82. PubMed ID: 20334367
[TBL] [Abstract][Full Text] [Related]
7. ATP-competitive inhibitors of the mammalian target of rapamycin: design and synthesis of highly potent and selective pyrazolopyrimidines.
Zask A; Verheijen JC; Curran K; Kaplan J; Richard DJ; Nowak P; Malwitz DJ; Brooijmans N; Bard J; Svenson K; Lucas J; Toral-Barza L; Zhang WG; Hollander I; Gibbons JJ; Abraham RT; Ayral-Kaloustian S; Mansour TS; Yu K
J Med Chem; 2009 Aug; 52(16):5013-6. PubMed ID: 19645448
[TBL] [Abstract][Full Text] [Related]
8. Triazines incorporating (R)-3-methylmorpholine are potent inhibitors of the mammalian target of rapamycin (mTOR) with selectivity over PI3Kalpha.
Richard DJ; Verheijen JC; Yu K; Zask A
Bioorg Med Chem Lett; 2010 Apr; 20(8):2654-7. PubMed ID: 20223664
[TBL] [Abstract][Full Text] [Related]
9. Novel purine and pyrazolo[3,4-d]pyrimidine inhibitors of PI3 kinase-alpha: Hit to lead studies.
Gilbert AM; Nowak P; Brooijmans N; Bursavich MG; Dehnhardt C; Santos ED; Feldberg LR; Hollander I; Kim S; Lombardi S; Park K; Venkatesan AM; Mallon R
Bioorg Med Chem Lett; 2010 Jan; 20(2):636-9. PubMed ID: 19969455
[TBL] [Abstract][Full Text] [Related]
10. Discovery of potent and selective inhibitors of the mammalian target of rapamycin (mTOR) kinase.
Nowak P; Cole DC; Brooijmans N; Bursavich MG; Curran KJ; Ellingboe JW; Gibbons JJ; Hollander I; Hu Y; Kaplan J; Malwitz DJ; Toral-Barza L; Verheijen JC; Zask A; Zhang WG; Yu K
J Med Chem; 2009 Nov; 52(22):7081-9. PubMed ID: 19848404
[TBL] [Abstract][Full Text] [Related]
11. The discovery and optimisation of pyrido[2,3-d]pyrimidine-2,4-diamines as potent and selective inhibitors of mTOR kinase.
Malagu K; Duggan H; Menear K; Hummersone M; Gomez S; Bailey C; Edwards P; Drzewiecki J; Leroux F; Quesada MJ; Hermann G; Maine S; Molyneaux CA; Le Gall A; Pullen J; Hickson I; Smith L; Maguire S; Martin N; Smith G; Pass M
Bioorg Med Chem Lett; 2009 Oct; 19(20):5950-3. PubMed ID: 19762236
[TBL] [Abstract][Full Text] [Related]
12. Pyrazolopyrimidines as highly potent and selective, ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 1-substituent.
Curran KJ; Verheijen JC; Kaplan J; Richard DJ; Toral-Barza L; Hollander I; Lucas J; Ayral-Kaloustian S; Yu K; Zask A
Bioorg Med Chem Lett; 2010 Feb; 20(4):1440-4. PubMed ID: 20089401
[TBL] [Abstract][Full Text] [Related]
13. Novel benzofuran-3-one indole inhibitors of PI3 kinase-alpha and the mammalian target of rapamycin: hit to lead studies.
Bursavich MG; Brooijmans N; Feldberg L; Hollander I; Kim S; Lombardi S; Park K; Mallon R; Gilbert AM
Bioorg Med Chem Lett; 2010 Apr; 20(8):2586-90. PubMed ID: 20303263
[TBL] [Abstract][Full Text] [Related]
14. Incorporation of water-solubilizing groups in pyrazolopyrimidine mTOR inhibitors: discovery of highly potent and selective analogs with improved human microsomal stability.
Richard DJ; Verheijen JC; Curran K; Kaplan J; Toral-Barza L; Hollander I; Lucas J; Yu K; Zask A
Bioorg Med Chem Lett; 2009 Dec; 19(24):6830-5. PubMed ID: 19896845
[TBL] [Abstract][Full Text] [Related]
15. Discovery and bioactivity of 4-(2-arylpyrido[3',2':3,4]pyrrolo[1,2-f][1,2,4]triazin-4-yl) morpholine derivatives as novel PI3K inhibitors.
Wang J; Wang X; Chen Y; Chen S; Chen G; Tong L; Meng L; Xie Y; Ding J; Yang C
Bioorg Med Chem Lett; 2012 Jan; 22(1):339-42. PubMed ID: 22130133
[TBL] [Abstract][Full Text] [Related]
16. Discovery of 2-ureidophenyltriazines bearing bridged morpholines as potent and selective ATP-competitive mTOR inhibitors.
Zask A; Verheijen JC; Richard DJ; Kaplan J; Curran K; Toral-Barza L; Lucas J; Hollander I; Yu K
Bioorg Med Chem Lett; 2010 Apr; 20(8):2644-7. PubMed ID: 20227881
[TBL] [Abstract][Full Text] [Related]
17. Exploring the PI3K alpha and gamma binding sites with 2,6-disubstituted isonicotinic derivatives.
Cherian PT; Koikov LN; Wortman MD; Knittel JJ
Bioorg Med Chem Lett; 2009 Apr; 19(8):2215-9. PubMed ID: 19297156
[TBL] [Abstract][Full Text] [Related]
18. Discovery of highly potent and selective type I B-Raf kinase inhibitors.
Wang X; Berger DM; Salaski EJ; Torres N; Hu Y; Levin JI; Powell D; Wojciechowicz D; Collins K; Frommer E
Bioorg Med Chem Lett; 2009 Dec; 19(23):6571-4. PubMed ID: 19854649
[TBL] [Abstract][Full Text] [Related]
19. A hit to lead discovery of novel N-methylated imidazolo-, pyrrolo-, and pyrazolo-pyrimidines as potent and selective mTOR inhibitors.
Lee W; Ortwine DF; Bergeron P; Lau K; Lin L; Malek S; Nonomiya J; Pei Z; Robarge KD; Schmidt S; Sideris S; Lyssikatos JP
Bioorg Med Chem Lett; 2013 Sep; 23(18):5097-104. PubMed ID: 23932790
[TBL] [Abstract][Full Text] [Related]
20. Structure-based optimization of morpholino-triazines as PI3K and mTOR inhibitors.
Poulsen A; Williams M; Nagaraj HM; William AD; Wang H; Soh CK; Xiong ZC; Dymock B
Bioorg Med Chem Lett; 2012 Jan; 22(2):1009-13. PubMed ID: 22197143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
